Registered title, quoted from ClinicalTrials.gov
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shantou University Medical College hospitals; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07071103, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Patients with metastatic solid tumors (of any histology) without standard therapy options, who have previously received immunotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with anti-angiogenesis treatment and have shown disease progression.
Inclusion criterion 5
Patients have complete clinical and pathological information.
Inclusion criterion 8
Patients who have received pelvic and abdominal radiation therapy within 6 months prior to enrollment.
Exclusion criterion 4
The adverse reactions from prior treatment have not yet recovered to a CTCAE5.0 rating of ≤ 1 (excluding toxicity that has been determined to be risk-free, such as fatigue or hair loss).
Exclusion criterion 5
ECOG level 0-2.
Inclusion criterion 2
At least one accessible and measurable lesion should be selected as the target lesion for observation according to RECIST criteria.
Inclusion criterion 4
Active hepatitis B, hepatitis C, HIV, or syphilis.
Exclusion criterion 8
Pregnant or breastfeeding women.
Exclusion criterion 12
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07071103, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥18 years, ≤80 years, regardless of gender.
- ECOG level 0-2.
- Expected life span>3 months.
- At least one accessible and measurable lesion should be selected as the target lesion for observation according to RECIST criteria.
- Patients with metastatic solid tumors (of any histology) without standard therapy options, who have previously received immunotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with anti-angiogenesis treatment and have shown disease progression.
- Patients should not be considered eligible for surgical treatment.
- Patients with brain metastases that are assessed as clinically stable after treatment through repeated CT and/or MRI scans are eligible.
- Patients have complete clinical and pathological information.
- Patients should not be borthered by any psychological, family, social or geographical conditions that may hinder compliance with the research protocol.
- Patients should be able to understand the informed consent form, voluntarily participate, and sign the informed consent form.
- Other indicators accord with the general inclusion criteria for clinical trials.
Exclusion Criteria:
- Patients with contraindications to radiation therapy and immunotherapy.
- Previous occurrence of unacceptable immune related toxic side effects (immune myocarditis, pneumonia, etc.).
- Patients who were assessed as hyperprogressive disease (HPD).
- Patients who have received pelvic and abdominal radiation therapy within 6 months prior to enrollment.
- The adverse reactions from prior treatment have not yet recovered to a CTCAE5.0 rating of ≤ 1 (excluding toxicity that has been determined to be risk-free, such as fatigue or hair loss).
- Patients with active uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment.
- Significant liver or kidney dysfunction (i.e., laboratory values >3 times the upper limit of normal).
- Active hepatitis B, hepatitis C, HIV, or syphilis.
- Brain disorders, symptomatic central nervous system (CNS) or meningeal metastases, or impaired cognitive function.
- Hypersensitivity to any drug included in the trial.
- Drug and/or alcohol abuse.
- Pregnant or breastfeeding women.
- Concurrent participation in another therapeutic clinical trial.
- Poorly controlled pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence within ≤14 days after intervention).
- Major surgery within 30 days.
- Use of antibiotics, antifungals, antivirals, antiparasitics, or probiotics within 4 weeks before enrollment.
Quoted from ClinicalTrials.gov, NCT07071103, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07071103, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.